Shuai Zha

Shuai Zha

Auto-generated profile, based on publicly available information

Shuai Zha

School of laboratory Medicine Hubei University of Chinese Medicine Wuhan China

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2022 in Small
Verified
Journal Article
Closed access
HLHengde Li
Hengde Li
SZShuai Zha
Shuai Zha
HLHaolan Li
Haolan Li
HLHaitao Liu
Haitao Liu
KWKa-Leung Wong
Ka-Leung Wong
AAANGELO ALL
ANGELO ALL

6 January 2021 in Advanced Science
Verified
Journal Article
Open access
PDF file
SZShuai Zha
Shuai Zha
HCHo‐Fai Chau
Ho‐Fai Chau
WCWai Yin Chau
Wai Yin Chau
LCLai Sheung Chan
Lai Sheung Chan
JLJun Lin
Jun Lin
KWKa-Leung Wong
Ka-Leung Wong
Using Epstein‐Barr virus (EBV)‐induced cancer cells and HeLa cells as a comparative study model, a novel and safe dual‐EBV‐oncoproteins‐targeting pH‐responsive peptide engineering, coating, and guiding approach to achieve precision targeting and treatment strategy against EBV‐associated cancers is introduced. Individual functional peptide sequences that specifically bind to two overexpressed EBV‐specific oncoproteins, EBNA1 (a latent cellular protein) and LMP1 (a transmembrane protein), are engineered in three different ways and incorporated with a pH‐sensitive tumor microenvironment (TME)‐cleavable linker onto the upconversion nanoparticles (UCNP) NaGdF4:Yb3+, Er3+@NaGdF4 (UCNP‐Pn, n = 5, 6, and 7). A synergistic combination of the transmembrane LMP1 targeting ability and the pH responsiveness of UCNP‐Pn is found to give specific cancer differentiation with higher cellular uptake and accumulation in EBV‐infected cells, thus a lower dose is needed and the side effects and health risks from treatment would be greatly reduced. It also gives responsive UC signal enhancement upon targeted dual‐protein binding and shows efficacious EBV cancer inhibition in vitro and in vivo. This is the first example of simultaneous imaging and inhibition of two EBV latent proteins, and serves as a blueprint for next‐generation peptide‐guided precision delivery nanosystem for the safe monitoring and treatment against one specific cancer.

19 October 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HLHongguang Li
Hongguang Li
CXChen Xie
Chen Xie
RLRongfeng Lan
Rongfeng Lan
SZShuai Zha
Shuai Zha
CCChi-Fai Chan
Chi-Fai Chan
KWKa-Leung Wong
Ka-Leung Wong

14 February 2022 in Advanced Healthcare Materials
Verified
Journal Article
Closed access
PDF file
SZShuai Zha
Shuai Zha
KWKa-Leung Wong
Ka-Leung Wong
AAANGELO ALL
ANGELO ALL

11 December 2017 in Inorganic Chemistry
Verified
Journal Article
Closed access
Bao GuochenBao Guochen
Bao Guochen
SZShuai Zha
Shuai Zha
ZLZhenyu Liu
Zhenyu Liu
YFYan-Ho Fung
Yan-Ho Fung
CCChi-Fai Chan
Chi-Fai Chan
KWKa-Leung Wong
Ka-Leung Wong

6 August 2018 in Nanoscale
Verified
Journal Article
Closed access
PDF file
SZShuai Zha
Shuai Zha
YFYan Ho Fung
Yan Ho Fung
HCHo-Fai Chau
Ho-Fai Chau
PMPing'AN Ma
Ping'AN Ma
Jun LinJun Lin
Jun Lin
KWKa-Leung Wong
Ka-Leung Wong
Responsive emission enhancement was observed between EBNA1 and dual-function EBNA1-targeting nanoprobe UCNP-P 4 , monitoring and inhibition of EBV-associated tumor is achieved.